These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 17934179

  • 1. Injury among stimulant-treated youth with ADHD.
    Marcus SC, Wan GJ, Zhang HF, Olfson M.
    J Atten Disord; 2008 Jul; 12(1):64-9. PubMed ID: 17934179
    [Abstract] [Full Text] [Related]

  • 2. Symptoms of attention-deficit/hyperactivity disorder following traumatic brain injury in children.
    Levin H, Hanten G, Max J, Li X, Swank P, Ewing-Cobbs L, Dennis M, Menefee DS, Schachar R.
    J Dev Behav Pediatr; 2007 Apr; 28(2):108-18. PubMed ID: 17435461
    [Abstract] [Full Text] [Related]

  • 3. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.
    Winterstein AG, Gerhard T, Shuster J, Zito J, Johnson M, Liu H, Saidi A.
    Ann Pharmacother; 2008 Jan; 42(1):24-31. PubMed ID: 18042808
    [Abstract] [Full Text] [Related]

  • 4. Utilization patterns of stimulants in ADHD in the Medicaid population: a retrospective analysis of data from the Texas Medicaid program.
    Lawson KA, Johnsrud M, Hodgkins P, Sasané R, Crismon ML.
    Clin Ther; 2012 Apr; 34(4):944-956.e4. PubMed ID: 22444786
    [Abstract] [Full Text] [Related]

  • 5. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A.
    Pediatrics; 2007 Dec; 120(6):e1494-501. PubMed ID: 18055666
    [Abstract] [Full Text] [Related]

  • 6. Combination therapy patterns and predictors of ADHD in commercially insured and Medicaid populations.
    Molife C, Bernauer MJ, Farr AM, Haynes VS, Kelsey D.
    Postgrad Med; 2012 Sep; 124(5):7-22. PubMed ID: 23095422
    [Abstract] [Full Text] [Related]

  • 7. Pharmacotherapy with atomoxetine for US children and adolescents.
    Bhatara VS, Aparasu RR.
    Ann Clin Psychiatry; 2007 Sep; 19(3):175-80. PubMed ID: 17729019
    [Abstract] [Full Text] [Related]

  • 8. Emergency department use and costs for youth with attention-deficit/hyperactivity disorder: associations with stimulant treatment.
    Leibson CL, Barbaresi WJ, Ransom J, Colligan RC, Kemner J, Weaver AL, Katusic SK.
    Ambul Pediatr; 2006 Sep; 6(1):45-53. PubMed ID: 16443183
    [Abstract] [Full Text] [Related]

  • 9. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B, Sopko MA, Ehret MJ, Paulino RE, Goldberg KR, Angstadt K, Bogart GT.
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [Abstract] [Full Text] [Related]

  • 10. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA, Pliszka SR.
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [Abstract] [Full Text] [Related]

  • 11. Attention deficit hyperactivity disorder and increased risk of injury.
    Merrill RM, Lyon JL, Baker RK, Gren LH.
    Adv Med Sci; 2009 Jun; 54(1):20-6. PubMed ID: 19586835
    [Abstract] [Full Text] [Related]

  • 12. Prescribed stimulant use by Western Australians with Attention Deficit Hyperactivity Disorder (ADHD): does amount dispensed exceed the expected authorised use?
    Calver J, Sanfilippo F, Preen D, Bulsara M.
    Aust N Z J Public Health; 2007 Dec; 31(6):533-9. PubMed ID: 18081573
    [Abstract] [Full Text] [Related]

  • 13. An analysis of patient adherence to treatment during a 1-year, open-label study of OROS methylphenidate in children with ADHD.
    Faraone SV, Biederman J, Zimmerman B.
    J Atten Disord; 2007 Sep; 11(2):157-66. PubMed ID: 17494833
    [Abstract] [Full Text] [Related]

  • 14. Persistence of stimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Palli SR, Kamble PS, Chen H, Aparasu RR.
    J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):139-48. PubMed ID: 22364400
    [Abstract] [Full Text] [Related]

  • 15. Trends in medication treatment for ADHD.
    Castle L, Aubert RE, Verbrugge RR, Khalid M, Epstein RS.
    J Atten Disord; 2007 May; 10(4):335-42. PubMed ID: 17449832
    [Abstract] [Full Text] [Related]

  • 16. Identified attention-deficit/hyperactivity disorder and medically attended, nonfatal injuries: US school-age children, 1997-2002.
    Pastor PN, Reuben CA.
    Ambul Pediatr; 2006 May; 6(1):38-44. PubMed ID: 16443182
    [Abstract] [Full Text] [Related]

  • 17. Child characteristics and receipt of stimulant medications: a population-based study.
    Miller AR, Kohen D, Johnston C.
    Ambul Pediatr; 2008 May; 8(3):175-81. PubMed ID: 18501864
    [Abstract] [Full Text] [Related]

  • 18. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations.
    Hammerness PG, Perrin JM, Shelley-Abrahamson R, Wilens TE.
    J Am Acad Child Adolesc Psychiatry; 2011 Oct; 50(10):978-90. PubMed ID: 21961773
    [Abstract] [Full Text] [Related]

  • 19. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion.
    Faraone SV, Wilens TE.
    J Clin Psychiatry; 2007 Oct; 68 Suppl 11():15-22. PubMed ID: 18307377
    [Abstract] [Full Text] [Related]

  • 20. ADHD and the rise in stimulant use among children.
    Mayes R, Bagwell C, Erkulwater J.
    Harv Rev Psychiatry; 2008 Oct; 16(3):151-66. PubMed ID: 18569037
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.